Publications

At Braeburn, we are leveraging our focus on opioid use disorder to work with the healthcare community and advance research, education and support to help end the opioid addiction epidemic.

List of Publications

JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.1052. Copyright © (2018) American Medical Association. All rights reserved.

JAMA Psychiatry. 2017;74(9):894–902. doi:10.1001/jamapsychiatry.2017.1874. Copyright © (2017) American Medical Association. All rights reserved.

Journal of Substance Abuse Treatment. Volume 78, 22 – 29. Copyright © 2017 Elsevier Inc. All rights reserved.

Advances in Therapy (2017) 34: 560. https://doi.org/10.1007/s12325-016-0472-9. Copyright © Springer Healthcare 2017.

Poster Presentations

2018
ASAM (American Society of Addiction Medicine): April 12-13, San Diego, California
Transitioning patients from sublingual to injectable weekly and monthly buprenorphine.
Frost M, Bailey G, Kim S, Budilovsky-Kelley N
AMCP (Academy of Managed Care Pharmacy): April 23-26, Boston, Massachusetts
An efficacy and safety comparison of CAM2038 vs SL BPN/NX for the treatment of patients with OUD who inject opioids
Frost M, Carter J, Budilovsky-Kelley N
CPDD (The College on Problems of Drug Dependence): June 11-12, San Diego, California
Phase 3 trial comparing depot buprenorphine (CAM2038) to sublingual buprenorphine/naloxone for OUD treatment: Subanalysis among persons with heroin as the primary opioid of abuse
Frost M, Lofwall M, Bailey, G, Walsh S, Beacker M, Budilovsky-Kelley N, Tiberg F
An efficacy and safety comparison of CAM2038 vs SL BPN/NX for the treatment of patients with OUD who inject opioids

Bailey F, Frost M, Lofwall M, Walsh S, Budilovsky-Kelley N, Tiberg F

2017
AMCP (Academy of Managed Care Pharmacy): March 27-30, Denver, Colorado
Employing bayesian-calibrated microsimulation to assess the cost-effectiveness of long acting injectable buprenorphine versus sublingual buprenorphine to treat opioid use disorder
Carter J, Dammerman R, Frost M, Tiberg F
AMCP Nexus (Academy of Managed Care Pharmacy): October 16-19, Dallas, Texas
Determining the economic impact of medication non-adherence in persons treated with depot-injectable or sublingual buprenorphine for opioid use disorder
Carter J, Frost M, Sanjurjo V
ATHS (Addictions Toxicomanies Hépatites SIDA): October 17-20, Biarritz, France
Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for opioid use disorder: European and Australian experience
Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Strang J, Kim S, Tiberg F
Lisbon Addictions October 24-26, Lisbon, Portugal
Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for opioid use disorder
Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Strang J, Kim S, Tiberg F
SSA (Society for the Study of Addiction): November 9-10, Newcastle, UK
Long-term safety, tolerability and effectiveness of weekly and monthly buprenorphine depots (CAM2038) for treatment of opioid dependence: A European, Australian and U.S. Phase 3 study
Strang J, Dunlop A, Frost M, Lintzeris N, Nunes E, Bailey G, Billeskov Jansen J, Chemnitz Frey L, Weber B, Kim S, Tiberg F

Define the future at Braeburn...together.

Join Our Team